Most Recent
Birkenstock has succeeded in securing trade mark protection for the shape of four of its shoes, a boon to the German shoe maker as it fights knock-offs of its popular sandals.
Seeking to quash search orders won by metals company Fortescue against former employees who founded a green iron rival, a lawyer for the start-up has said three terabytes of data were indiscriminately copied, including confidential, privileged and irrelevant material.
Fund manager Real Asset Management has appealed a ruling which upheld mortgage broker RAMS’ bid to block the registration of two RAM trade marks.
The French association representing wine producers from Champagne has discontinued its lawsuit against an Australian retailer after it agreed to only use seed extract from the Champagne region of France.
Metal mining company Fortescue hired private investigators to spy on former employees who created green iron start-up Element Zero, sifting through their mail, taking photos of their children and following them to Kmart, a court has heard.
The Dietitians Association of Australia can't register a logo featuring the words 'accredited nutritionist' as a trade mark, with a delegate agreeing with a competing nutritionist group that the association should not have a monopoly over the highly descriptive term.
Energy retailer Origin Energy has hit back at a trade mark infringement suit filed by internet provider Origin Net, arguing that its mark should be revoked and accusing Origin Net of misleading and deceptive conduct.
K&L Gates has lured three partners from rival firms to bolster its corporate, IP and real estate offerings across the country, including a former principal of Davies Collison Cave.
Tesla CEO Robyn Denholm has lodged an appeal that must convince the Federal Court that her family office's use of the 'Wollemi' trade mark was not just private and personal, but use in trade or commerce that benefitted third parties, not just the family.
A judge has rejected Samsung Bioepis' bid to discover research and development documents from Pfizer as it seeks to invalidate the drug giant's patent for its blockbuster autoimmune drug Enbrel, agreeing with Pfizer that it may be "no more than an exercise in fishing".